OraSure Technologies (OSUR) Lowered to “C+” at TheStreet

TheStreet downgraded shares of OraSure Technologies (NASDAQ:OSUR) from a b rating to a c+ rating in a report published on Thursday.

A number of other research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of OraSure Technologies from a strong-buy rating to a hold rating in a research report on Wednesday. ValuEngine raised shares of OraSure Technologies from a hold rating to a buy rating in a research report on Tuesday. BidaskClub raised shares of OraSure Technologies from a strong sell rating to a sell rating in a research report on Wednesday, October 24th. Raymond James reissued a mkt perform rating on shares of OraSure Technologies in a research report on Tuesday, October 23rd. Finally, Stephens downgraded shares of OraSure Technologies from an overweight rating to an equal weight rating in a research report on Monday, July 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. OraSure Technologies presently has a consensus rating of Hold and a consensus price target of $20.50.

OraSure Technologies stock traded down $0.19 during mid-day trading on Thursday, reaching $13.01. 796,704 shares of the company traded hands, compared to its average volume of 550,183. The company has a market cap of $900.47 million, a P/E ratio of 25.51, a PEG ratio of 3.46 and a beta of 1.52. OraSure Technologies has a 52-week low of $12.50 and a 52-week high of $22.22.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, November 7th. The medical instruments supplier reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.02. The business had revenue of $45.90 million for the quarter, compared to the consensus estimate of $44.50 million. OraSure Technologies had a net margin of 9.49% and a return on equity of 6.68%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.09 EPS. As a group, sell-side analysts expect that OraSure Technologies will post 0.34 EPS for the current fiscal year.

In other news, Director Charles W. Patrick sold 8,000 shares of the company’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $16.29, for a total value of $130,320.00. Following the sale, the director now directly owns 54,298 shares of the company’s stock, valued at approximately $884,514.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.90% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new stake in shares of OraSure Technologies in the 2nd quarter worth about $122,000. Cubist Systematic Strategies LLC purchased a new stake in shares of OraSure Technologies in the 1st quarter worth about $139,000. Engineers Gate Manager LP purchased a new stake in shares of OraSure Technologies in the 2nd quarter worth about $197,000. Xact Kapitalforvaltning AB purchased a new stake in shares of OraSure Technologies in the 2nd quarter worth about $198,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of OraSure Technologies in the 3rd quarter worth about $187,000. 92.00% of the stock is currently owned by hedge funds and other institutional investors.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Story: Can individual investors take part in an IPO?

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply